Yan Cheng, PhD

Associate Member

Research Program:

Cancer Biology

Faculty Rank:

Assistant Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Internal Med Myeloma Research

Cancer Research Interest

Disease Site Focus: Multiple Myeloma, Prostate
Research Focus Area: Treatment, Diagnosis/ Prognosis
Type of Research: Translational
Research Keywords: Tumor immune microenvironment, Neural regulation of tumor, CAR-T cell therapies
Research Interest Statement: My research interest is to (1) investigate how immune cells and neural components within the tumor microenvironment contribute to cancer resistance; (2) develope novel immune therapies and harnessing the nerve system for cancer treatment.

Contact Information

Email Address: YCHENG@UAMS.EDU
Profiles Research Networking Software: View Profile

Recent Publications

Cheng Y, Sun F, Alapat DV, [et al.]. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood cancer journal. 2024 14(1):194. PMID: 39505839. PMCID: PMC11541562.
Guo W, Strouse C, Mery D, [et al., including Cheng Y]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
Li JR, Arsang-Jang S, Cheng Y, [et al.]. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood cancer journal. 2024 14(1):38. PMID: 38443358. PMCID: PMC10915134.
Guo W, Zhan Y, Mery D, [et al., including Cheng Y]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
Sun F, Cheng Y, Wanchai V, [et al.]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
Sun F, Cheng Y, Chen JR, [et al.]. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of clinical investigation. 2023. PMID: 37883186. PMCID: PMC10760955.
Cheng Y, Sun F, Alapat DV, [et al.]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
Pisano MD, Sun F, Cheng Y, [et al.]. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma. Haematologica. 2023. PMID: 37439384. PMCID: PMC10690922.
Sun F, Cheng Y, Ying J, [et al.]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
Gai D, Chen JR, Stewart JP, [et al., including Cheng Y]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
Cheng Y, Sun F, Thornton K, [et al.]. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022. PMID: 35794249. PMCID: PMC9355869.
Shi Y, Sun F, Cheng Y, [et al.]. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Molecular cancer therapeutics. 2022 21(4):502-510. PMID: 35086951. PMCID: PMC8983490.
Sun F, Cheng Y, Riordan JD, [et al.]. WDR26 and MTF2 are therapeutic targets in multiple myeloma. Journal of hematology & oncology. 2021 14(1):203. PMID: 34876184. PMCID: PMC8650373.
Cheng Y, Sun F, D'Souza A, [et al.]. Autonomic nervous system control of multiple myeloma. Blood reviews. 2021 46:100741. PMID: 32807576. PMCID: PMC7876165.
Zhang Y, Pisano M, Li N, [et al., including Cheng Y]. Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related peripheral neuropathy. Cellular signalling. 2021 78:109872. PMID: 33290841.
Pisano M, Cheng Y, Sun F, [et al.]. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Frontiers in immunology. 2021 12:667054. PMID: 34149703. PMCID: PMC8206561.
Wu H, You L, Li Y, [et al., including Cheng Y]. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer research. 2020 80(13):2927-2939. PMID: 32341037. PMCID: PMC9601976.